Active inflammation, rather than the presence of a fistula in itself, is the main driver of reduced health-related quality of life (HRQoL) in Crohn’s disease (CD), according to a study of 209 patients published in Digestive Diseases and Sciences. The research examined how disease phenotype, treatment approach and clinical disease activity each relate to patient wellbeing, and found that measures of active luminal and perianal inflammation correlated with quality of life whilst fistula presence, prior surgery and biologic exposure did not.
Background Context
Fistulising Crohn’s disease represents a particularly challenging manifestation of CD in which abnormal channels form between the intestine and other organs or the skin surface. This penetrating disease behaviour affects approximately one third of Crohn’s disease patients over the course of their condition and often requires intensive medical therapy or surgical intervention. Perianal fistulae are the most common type, though fistulae can develop between loops of bowel or connect to the bladder or vagina. The complexity of managing fistulising disease, combined with its physical symptoms and potential for repeated procedures, has long been recognised as a burden on patients, but comprehensive data on quality of life outcomes have remained limited.
Key Findings
This cross-sectional study assessed 209 adults with Crohn’s disease at a tertiary IBD clinic (mean age 38.6 years, 36.8% female), of whom 50.7% had fistulising disease. Quality of life was measured with the Inflammatory Bowel Disease Questionnaire (IBDQ) and its four subdomains; disease activity was measured with the Crohn’s Disease Activity Index (CDAI) and, in those with perianal disease, the Perianal Disease Activity Index (PDAI).
The strongest associations were with active inflammation rather than with disease phenotype. CDAI showed a moderate inverse correlation with total IBDQ score (rho = -0.538, p < 0.001), and PDAI was also negatively correlated with total IBDQ score (rho = -0.372, p = 0.001). Female patients reported lower quality-of-life scores.
Notably, several factors that might be expected to reduce quality of life did not do so to a statistically significant degree: the presence of a fistula itself, smoking, previous surgery, and prior exposure to biologic therapy. The authors concluded that active luminal and perianal inflammation, rather than fistula presence alone, appears to be the principal determinant of HRQoL in Crohn’s disease.
Clinical Relevance
These findings suggest that in fistulising Crohn’s disease, controlling inflammation matters more to how a patient actually feels than the anatomical presence of a fistula tract does. For gastroenterologists and IBD specialist nurses, that reinforces the value of treating to objective remission rather than judging burden by phenotype alone, and it argues against assuming that a patient with a fistula necessarily has poorer quality of life than one without.
The study is cross-sectional and single-centre, so it shows association rather than cause and effect, and it cannot track how quality of life changes over time. The finding that biologic exposure and prior surgery were not significantly associated with HRQoL should be read in that light: it does not mean these treatments are ineffective, only that in this cohort they did not independently predict quality-of-life scores once inflammatory activity was accounted for.
Reference
Kani HT, Kaldirim Armutcuoglu Y, Ergenc I, Ozsarac B, Sahin BN, Kaya G, Oztemiz B, Demir BC, Atug O, Ozen Alahdab Y. The Impact of Fistulizing Disease, Treatment Modalities, and Clinical Activity on Health-Related Quality of Life in Crohn’s Disease. Dig Dis Sci. Published online 27 July 2026. doi:10.1007/s10620-026-10135-0
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.